Delayed Nyse 04:01:55 2023-09-21 pm EDT |
|
5-day change | 1st Jan Change | |
199.18 USD | -3.04% | -6.47% | -2.79% |
Sep. 21 | Iqvia Holdings Insider Sold Shares Worth $5,700,340, According to a Recent SEC Filing | MT |
Sep. 13 | Transcript : IQVIA Holdings Inc. - Special Call | CI |
Financials (USD)
Sales 2023 * | 15,123 M | Sales 2024 * | 16,269 M | Capitalization | 36 474 M |
---|---|---|---|---|---|
Net income 2023 * | 1,249 M | Net income 2024 * | 1,491 M | EV / Sales 2023 * | 3,17x |
Net Debt 2023 * | 11,529 M | Net Debt 2024 * | 10,680 M | EV / Sales 2024 * | 2,90x |
P/E ratio 2023 * | 30,0x | P/E ratio 2024 * | 24,8x | Employees | - |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 70.52% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -3.04% | ||
1 week | -6.47% | ||
Current month | -10.53% | ||
1 month | -7.08% | ||
3 months | -6.85% | ||
6 months | +1.23% | ||
Current year | -2.79% |
1 week
197.64
211.59

1 month
197.64
227.14

Current year
177.00
241.86

1 year
165.75
241.86

3 years
146.00
285.61

5 years
81.79
285.61

10 years
40.10
285.61

Managers | Title | Age | Since |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 61 | 2016 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 62 | 2020 |
Jeffrey Spaeder
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Todd Sisitsky
BRD | Director/Board Member | 51 | 2015 |
Ari Bousbib
CHM | Chairman | 61 | 2016 |
John Leonard
BRD | Director/Board Member | 65 | 2015 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.92% | 2 M$ | -0.04% | - | |
1.54% | 30 M$ | +8.40% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-21 | 199.18 | -3.04% | 1,595,500 |
23-09-20 | 205.42 | -1.66% | 967,832 |
23-09-19 | 208.88 | -0.22% | 1,013,898 |
23-09-18 | 209.35 | -1.11% | 871,307 |
23-09-15 | 211.71 | -0.59% | 2,027,171 |
Delayed Quote Nyse, September 21, 2023 at 04:01 pm EDT
More quotes
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:
- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;
- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;
- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.
Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Calendar
2023-10-23
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy

Mean consensus
BUY
Number of Analysts
21
Last Close Price
199.18USD
Average target price
252.42USD
Spread / Average Target
+26.73%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
-2.79% | 36 474 M $ | |
-5.91% | 35 061 M $ | |
-44.20% | 38 147 M $ | |
+60.60% | 38 739 M $ | |
-26.85% | 21 731 M $ | |
+29.66% | 20 691 M $ | |
-11.21% | 15 112 M $ | |
-15.64% | 11 064 M $ | |
-19.57% | 10 498 M $ | |
-9.06% | 10 159 M $ |